

# Seiichiro Mitani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7197374/publications.pdf>

Version: 2024-02-01

49  
papers

375  
citations

933447

10  
h-index

839539

18  
g-index

49  
all docs

49  
docs citations

49  
times ranked

752  
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2022, 161, 44-54.	2.8	7
2	Safety and tolerability of anecaliximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study. , 2022, 10, e003518.		5
3	Myxoid liposarcoma originating in the retroperitoneum with metastasis to the calcaneus: a rare case report and review of literature. <i>Skeletal Radiology</i> , 2022, 51, 2053-2058.	2.0	2
4	Second primary malignancies in patients with clinical T1bN0 esophageal squamous cell carcinoma after definitive therapies: supplementary analysis of the JCOG trial: JCOG0502. <i>Journal of Gastroenterology</i> , 2022, , .	5.1	4
5	A phase 1b study of anecaliximab in combination with S-1 plus platinum in Japanese patients with gastric adenocarcinoma. <i>Scientific Reports</i> , 2022, 12, .	3.3	2
6	A triplet combination of FOLFOXIRI plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: a dose-escalation phase 1b study. <i>International Journal of Clinical Oncology</i> , 2021, 26, 701-707.	2.2	2
7	Safety and efficacy of cetuximab-containing chemotherapy after immune checkpoint inhibitors for patients with squamous cell carcinoma of the head and neck: a single-center retrospective study. <i>Anti-Cancer Drugs</i> , 2021, 32, 95-101.	1.4	16
8	Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer. <i>BMC Cancer</i> , 2021, 21, 1159.	2.6	5
9	Risk of second primary malignancies after definitive treatment for esophageal cancer: A competing risk analysis. <i>Cancer Medicine</i> , 2020, 9, 394-400.	2.8	12
10	Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, FTD/TPI, with Ramucirumab Murine Version DC101 in a Mouse Syngeneic Cancer Transplantation Model. <i>Journal of Clinical Medicine</i> , 2020, 9, 4050.	2.4	2
11	A Phase II Study of Modified FOLFOX6 for Advanced Gastric Cancer Refractory to Standard Therapies. <i>Advances in Therapy</i> , 2020, 37, 2853-2864.	2.9	6
12	Phase I Study of Alternate-Day Administration of Sâ€, Oral Leucovorin, and Bevacizumab for Refractory Metastatic Colorectal Cancer. <i>Oncologist</i> , 2020, 25, e1614-e1620.	3.7	0
13	Glasgow Prognostic Score (GPS) and Tumor Response as Biomarkers of Nivolumab Monotherapy in Third- or Later-line Setting for Advanced Gastric Cancer. <i>In Vivo</i> , 2020, 34, 1921-1929.	1.3	9
14	Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance. <i>Cancers</i> , 2020, 12, 400.	3.7	50
15	Retrospective observational study of salvage line ramucirumab monotherapy for patients with advanced gastric cancer. <i>BMC Cancer</i> , 2020, 20, 338.	2.6	6
16	Efficacy of Cytotoxic Agents After Progression on Anti-PD-(L)1 Antibody for Pre-treated Metastatic Gastric Cancer. <i>Anticancer Research</i> , 2020, 40, 2247-2255.	1.1	16
17	Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features. <i>Scientific Reports</i> , 2019, 9, 10526.	3.3	9
18	2nd line bevacizumab(BEV) continuation chemotherapy(Cx) beyond early progression for metastatic colorectal cancer(mCRC). <i>Annals of Oncology</i> , 2019, 30, vi100.	1.2	0

#	ARTICLE	IF	CITATIONS
19	Combination of Oxaliplatin and 5-Fluorouracil/Leucovorin for Advanced Esophageal Squamous Cell Carcinoma Refractory or Intolerant to Standard Therapies. <i>Case Reports in Oncology</i> , 2019, 12, 304-310.	0.7	3
20	Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: a multicenter retrospective study. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1197-1203.	2.2	5
21	Prospective Survey of Financial Toxicity Measured by the Comprehensive Score for Financial Toxicity in Japanese Patients With Cancer. <i>Journal of Global Oncology</i> , 2019, 5, 1-8.	0.5	32
22	The impact of the Glasgow Prognostic Score on survival in second-line chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591882029.	3.2	12
23	A Prospective Trial Evaluating the Safety of a Shortened Infusion of Ramucirumab in Patients with Gastrointestinal Cancer. <i>Oncologist</i> , 2019, 24, 159-e66.	3.7	1
24	Panitumumab Provides Better Survival Outcomes Compared to Cetuximab for Metastatic Colorectal Cancer Patients Treated with Prior Bevacizumab within 6 Months. <i>Oncology</i> , 2019, 96, 132-139.	1.9	3
25	Phase Ib study of andeciximab (GS-5745, ADX) in combination with S-1+platinum chemotherapy in Japanese subjects with advanced gastric or GEJ adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 53-53.	1.6	0
26	Phase 1b study of andeciximab (GS-5745, ADX) as monotherapy and in combination with nivolumab (nivo) in Japanese subjects with gastric or GEJ adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 137-137.	1.6	2
27	Successful Treatment of Cardiac Angiosarcoma Associated with Disseminated Intravascular Coagulation with Nab-Paclitaxel: A Case Report and Review of the Literature. <i>Case Reports in Oncology</i> , 2018, 10, 863-870.	0.7	11
28	Morphologic Response and Tumor Shrinkage as Early Predictive Markers in Unresectable Colorectal Liver Metastases. <i>Anticancer Research</i> , 2018, 38, 6501-6506.	1.1	2
29	Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer. <i>Anticancer Research</i> , 2018, 38, 5859-5866.	1.1	42
30	A prospective survey of comprehensive score for financial toxicity in Japanese cancer patients: report on a pilot study. <i>Ecancermedalscience</i> , 2018, 12, 847.	1.1	31
31	A triplet combination with irinotecan, oxaliplatin, continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in RAS wild-type, metastatic colorectal cancer: A phase 1 dose finding study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 856-856.	1.6	2
32	Efficacy of cytotoxic agents after progression of anti-PD-(L)1 antibody for pretreated metastatic gastric cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 152-152.	1.6	0
33	Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: A multicenter retrospective study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 154-154.	1.6	0
34	Retrospective observational study of salvage line ramucirumab monotherapy (RAM) for patients (pts) with unresectable advanced gastric cancer (AGC) which was refractory to fluoropyrimidine and taxanes.. <i>Journal of Clinical Oncology</i> , 2018, 36, 129-129.	1.6	1
35	A prospective survey of comprehensive score for financial toxicity (COST) in Japanese cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e22128-e22128.	1.6	0
36	Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody. <i>Oncology</i> , 2017, 92, 205-212.	1.9	7

#	ARTICLE	IF	CITATIONS
37	Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy. <i>Medicine (United States)</i> , 2017, 96, 1-10.	1.0	29
38	No benefit from ramucirumab in first-line chemotherapy?. <i>Translational Gastroenterology and Hepatology</i> , 2017, 2, 30-30.	3.0	2
39	Peritoneum metastasis (PM) as a prognostic factor in metastatic gastric cancer (MGC) treated with anti-PD-1/PD-L1 monotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3051-3051.	1.6	1
40	Impact of sarcopenia on survival outcomes in patients (pts) with metastatic gastric cancer (mGC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 141-141.	1.6	1
41	Efficacy of bevacizumab in combination with doublet chemotherapy as first-line therapy in metastatic colorectal cancer according to KRAS status.. <i>Journal of Clinical Oncology</i> , 2017, 35, 744-744.	1.6	1
42	Efficacy of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS exon2 metastatic colorectal cancer previously treated with bevacizumab within 6 months.. <i>Journal of Clinical Oncology</i> , 2017, 35, 800-800.	1.6	2
43	FOLFOX as First-line Therapy for Gastric Cancer with Severe Peritoneal Metastasis. <i>Anticancer Research</i> , 2017, 37, 7037-7042.	1.1	21
44	Chemoradiotherapy versus surgery for clinical stage I esophageal squamous cell carcinoma: a long-term comparison. <i>Annals of Oncology</i> , 2016, 27, vii75.	1.2	0
45	Pseudocirrhosis in Gastric Cancer with Diffuse Liver Metastases after a Dramatic Response to Chemotherapy. <i>Case Reports in Oncology</i> , 2016, 9, 106-111.	0.7	10
46	A retrospective comparison between regorafenib and TAS-102 for refractory metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 723-723.	1.6	1
47	Effect of first-line molecular targeted agents on the efficacy of second-line bevacizumab-containing regimen for metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 748-748.	1.6	0
48	Survival outcome of metastatic adenocarcinoma of esophagogastric junction in the trastuzumab era.. <i>Journal of Clinical Oncology</i> , 2016, 34, 117-117.	1.6	0
49	Phase I study of alternate-day administration of S-1, oral leucovorin, and bevacizumab for refractory metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e14021-e14021.	1.6	0